Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Dieye, Tandakha N ^a   NDiaye, Birahim P ^a   Dieng, Alle B ^a   Fall, Marema ^a   Britain, Nathaniel ^b   Vermaak, Samantha ^b   Camara, Makhtar ^a   Diop Ndiaye, Halimatou ^a   Ngom Gueye, Ndeye Fatou ^a   Diaw, Papa A ^a   Toure Kane, Coumba ^a   Sow, Papa S ^a   Mboup, Souleymane ^a   McShane, Helen ^b  

^a Centre Hospitalier Universitaire Dakar   (Senegal)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; VIRUS RNA;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SENEGAL; TUBERCULOSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; MALE; MIDDLE AGED; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84879543995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067177     Document Type: Article

References (41)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC, (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama 282: 677-686.
2. (2011) Global tuberculosis control: WHO report 2011.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
4. de Colombani P, Banatvala N, Zaleskis R, Maher D, (2004) European framework to decrease the burden of TB/HIV. Eur Respir J 24: 493-501.
5. Corbett EL, Marston B, Churchyard GJ, De Cock KM, (2006) Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367: 926-937.
6. Bekker L-G, Wood R, (2010) The changing natural history of tuberculosis and HIV coinfection in an urban area of hyperendemicity. Clin Infect Dis 50Suppl 3: 208-214.
7. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, et al. (2005) How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191: 150-158.
8. Lawn SD, Myer L, Edwards D, Bekker L-G, Wood R, (2009) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23: 1717-1725.
9. Breen RAM, Smith CJ, Cropley I, Johnson MA, Lipman MCI, (2005) Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS 19: 1201-1206.
10. Lawn SD, Badri M, Wood R, (2005) Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19: 2109-2116.
11. Rodrigues LC, Diwan VK, Wheeler JG, (1993) Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 22: 1154-1158.
12. Trunz BB, Fine P, Dye C, (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180.
13. Hesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspan HB, et al. (2009) BCG vaccination in South African HIV-exposed infants-risks and benefits. S Afr Med J 99: 88-91.
14. Kaufmann SHE, Hussey G, Lambert P-H, (2010) New vaccines for tuberculosis. Lancet 375: 2110-2119.
15. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, et al. (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198: 544-552.
16. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
17. McShane H, Brookes R, Gilbert SC, Hill AV, (2001) Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69: 681-686.
18. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
19. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, et al. (2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 4: e5264.
20. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, et al. (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77: 3364-3373.
21. Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, et al. (2008) Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One 3.
22. Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, et al. (2006) Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 6: 522-528.
23. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet.
24. Dye C, Fine PE (2013) A major event for new tuberculosis vaccines. Lancet.
25. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
26. Minassian AM, Rowland R, Beveridge NER, Poulton ID, Satti I, et al. (2011) A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 1.
27. Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, et al. (2012) A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 185: 769-778.
28. Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, et al. (2007) Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2: e1052.
29. Ota MOC, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, et al. (2011) Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med 3: 88-88.
30. Plana M, Garcia F, Darwich L, Romeu J, Lopez A, et al. (2011) The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. Immunology 133: 318-328.
31. Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, et al. (2004) IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 104: 775-780.
32. Douek DC, (2002) The contribution of the thymus to immune reconstitution after hematopoietic stem-cell transplantation. Cytotherapy 4: 425-426.
33. Shearer GM, Clerici M, (1991) Early T-helper cell defects in HIV infection. AIDS 5: 245-253.
34. Sander CR, Pathan AA, Beveridge NE, Poulton I, Minassian A, et al. (2009) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179: 724-733.
35. Badri M, Wilson D, Wood R, (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359: 2059-2064.
36. Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, et al. (1999) Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 180: 1050-1056.
37. Schacker TW, Bosch RJ, Bennett K, Pollard R, Robbins GK, et al. (2010) Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr 54: 59-62.
38. Goldsack L, Kirman JR, (2007) Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis. Tuberculosis (Edinb) 87: 465-473.
39. Cowley SC, Elkins KL, (2003) CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 171: 4689-4699.
40. Wu CY, Kirman JR, Rotte MJ, Davey DF, Perfetto SP, et al. (2002) Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 3: 852-858.
41. Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci M, et al. (2003) Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 187: 270-278.